RxDoctor Payments Data

Gail Schattner, MD

Pulmonary Disease · New York, NYNPI 1710996764

Payments from drug & device makers

$1,319in general payments, 2019–2025

Across 3 payments — averaging $439.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K

What the payments were for

  • Consulting fees$1,30099%
  • Food & beverage$191%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$1,319

How this compares

$1,319 in reported general payments places this provider in the 50th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$1,636,045
Medicare patients
612
Services billed
48,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter223$219,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr103$55,321
NucalaMepolizumab13$42,485
Breo ElliptaFluticasone/Vilanterol81$39,585
Spiriva RespimatTiotropium Bromide34$32,097
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$31,522
Stiolto RespimatTiotropium Br/Olodaterol Hcl51$28,196
Incruse ElliptaUmeclidinium Bromide60$27,313
Advair HfaFluticasone Propion/Salmeterol60$26,017
SymbicortBudesonide/Formoterol Fumarate63$24,572
DuleraMometasone/Formoterol38$19,189
Arnuity ElliptaFluticasone Furoate36$14,235
Spiriva HandihalerTiotropium Bromide12$7,120
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$6,911
Fluticasone Propionate HfaFluticasone Propionate21$6,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$1,319$398,719516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →